Ishiguro Hideyuki, Kuwabara Yoshiyuki, Kimura Masahiro, Mitsui Akira, Ogawa Ryo, Fujii Yoshitaka
Dept. of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences.
Gan To Kagaku Ryoho. 2008 Nov;35(11):1931-3.
A 68-year-old man with lymph node metastasis of stomach pylorus pointed out by abdominal CT, was diagnosed as gastric cancer of the stomach pyloric region. Although an operation was performed, the lymph node metastasis of No. 13 had invaded the pancreas, and curative resection of the lymph node was impossible. After the operation, he was given combination chemotherapy with PTX combined S-1, and CDDP combined S-1. Progressive disease (PD) was confirmed by abdominal CT after both combination chemotherapies. Next, he was given combination chemotherapy with S-1 and CPT-11 (S-1 100 mg/body, day 1-14, CPT-11 125 mg/m(2) day 1 and 15 every 4 weeks). Disappearance of the lymph node metastasis and decrease of CA19-9 were confirmed after combination chemotherapy with S-1 and CPT-11. After six courses of the chemotherapy, recurrences are no longer seen. S-1+CPT-11 chemotherapy is considered very useful because the adverse events of this chemotherapy have been mild.
一名68岁男性,腹部CT显示胃幽门淋巴结转移,被诊断为胃幽门区胃癌。尽管进行了手术,但13号淋巴结转移已侵犯胰腺,无法进行淋巴结的根治性切除。术后,他接受了紫杉醇联合S-1以及顺铂联合S-1的联合化疗。两种联合化疗后经腹部CT证实疾病进展(PD)。接下来,他接受了S-1和伊立替康的联合化疗(S-1 100mg/体,第1 - 14天,伊立替康125mg/m²,每4周的第1天和第15天)。S-1和伊立替康联合化疗后证实淋巴结转移消失且CA19-9下降。化疗六个疗程后,未见复发。S-1 +伊立替康化疗被认为非常有效,因为该化疗的不良事件较轻。